EyePoint Pharmaceuticals, Inc. (EYPT)

EyePoint Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	271.16	281.41	95.78	178.74	45.06	22.36
Short-Term Investments	28.34	49.79	48.93	32.97	0	0
Cash & Cash Equivalents	299.5	331.2	144.71	211.71	45.06	22.36
Cash Growth	144.22%	128.87%	-31.65%	369.85%	101.48%	-42.55%
Receivables	3.02	0.81	15.5	18.35	9.45	11.37
Inventory	4.26	3.91	2.89	3.62	5.34	2.14
Other Current Assets	10.94	8.89	9.71	4.07	3.27	5.85
Total Current Assets	317.71	344.8	172.81	237.75	63.12	41.72
Property, Plant & Equipment	11.39	10.23	7.4	2.73	3.24	3.44
Goodwill and Intangibles	0	0	0	22.75	25.21	27.67
Other Long-Term Assets	0.15	0.15	0.15	0.15	0.15	0.15
Total Long-Term Assets	11.54	10.38	7.55	25.63	28.6	31.25
Total Assets	329.25	355.18	180.36	263.37	91.72	72.97
Accounts Payable	7.08	6.5	5.92	7.39	4.81	4.19
Deferred Revenue	50.49	59.28	14.76	15.63	16.56	0.02
Current Debt	0	0	10.48	0	0	0
Other Current Liabilities	5.01	-2.53	3.38	0.64	-6.48	7.31
Total Current Liabilities	62.58	63.26	34.54	23.66	14.89	11.52
Long-Term Debt	4.62	4.91	35.29	38.42	40.31	50.12
Other Long-Term Liabilities	12.11	20.69	14.16	16.91	17.98	3
Total Long-Term Liabilities	16.73	25.6	49.45	55.33	58.29	53.12
Total Liabilities	79.31	88.86	83.99	78.99	73.18	64.64
Total Debt	4.62	4.91	45.77	38.42	40.31	50.12
Debt Growth	-88.55%	-89.28%	19.12%	-4.68%	-19.58%	189.57%
Retained Earnings	-771.43	-742.15	-671.35	-569.1	-510.68	-465.29
Comprehensive Income	0.84	0.86	0.79	0.84	0.84	0.84
Shareholders' Equity	249.93	266.32	96.37	184.38	18.54	8.33
Net Cash / Debt	294.87	326.29	98.94	173.29	4.75	-27.76
Net Cash / Debt Growth	258.52%	229.78%	-42.90%	3546.59%	-	-
Net Cash Per Share	5.57	8.39	2.65	6.03	0.37	-2.66
Working Capital	255.13	281.54	138.27	214.09	48.23	30.2
Book Value Per Share	4.72	6.85	2.58	6.41	1.44	0.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).